SCHEMBL339851

SCHEMBL339851

COC(=O)c1ccnc(N)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 1/20 0.61
GABRD O14764 1/20 0.61
GABRA1 P14867 1/20 0.61
GABRB1 P18505 1/20 0.61
GABRG2 P18507 1/20 0.61
GABRB3 P28472 1/20 0.61
GABRA5 P31644 1/20 0.61
GABRA3 P34903 1/20 0.61
GABRA2 P47869 1/20 0.61
GABRB2 P47870 1/20 0.61
GABRA4 P48169 1/20 0.61
GABRE P78334 1/20 0.61
GABRA6 Q16445 1/20 0.61
GABRG1 Q8N1C3 1/20 0.61
GABRG3 Q99928 1/20 0.61
GABRQ Q9UN88 1/20 0.61
KDM4E B2RXH2 3/20 0.60
KDM6B O15054 1/20 0.60
KDM5C P41229 1/20 0.60
KDM4C Q9H3R0 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29437205 1.00 GABRP (0.61) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL2715680 0.98 GABRP (0.59) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL26093618 0.83 GABRP (0.63) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5542944 0.82 MKNK1 (0.67) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL70279 0.81 KDM4E (0.86) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL29894587 0.81 KDM4E (0.86) KDM4EKDM6BKDM5CKDM4CKDM2A
SCHEMBL256755 0.81 GABRP (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL27531467 0.81 GABRA1 (0.56) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL6740832 0.80 JMJD6 (0.55) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL5591077 0.80 JMJD6 (0.55) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 903 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115869923-B Oxygen absorbing material, preparation method thereof and prepared adsorption material capable of simultaneously adsorbing oxygen and organic solvent 威格科技(苏州)股份有限公司 2024-03-22 CN claimed
CN-117560981-A Method for optimizing quasi-two-dimensional blue light LED device by utilizing cooperation of two ligands 吉林大学 2024-02-13 CN claimed
CN-115869923-A Oxygen absorbing material, preparation method thereof and prepared adsorbing material capable of adsorbing oxygen and organic solvent simultaneously 威格科技(苏州)股份有限公司 2023-03-31 CN claimed
CN-115192813-A Micro-flow injection pump 中国计量大学 2022-10-18 CN claimed
CN-112682320-A Single-stage single-suction horizontal centrifugal pump 亚什兰水泵无锡有限公司 2021-04-20 CN claimed
CN-106893239-B A kind of cushion blocking of centrifugal pump 贝德科技有限公司 2019-03-05 CN claimed
CN-106893239-A A kind of cushion blocking of centrifugal pump 浙江贝德泵业有限公司 2017-06-27 CN claimed
CN-102333779-A Benzopyran and benzoxex PI3K inhibitor compounds and methods of use GENENTECH INC 2012-01-25 CN claimed
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2026-05-19 US disclosed
US-12630497-B2 Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2026-05-19 US disclosed
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof LG CHEM, LTD. (KR) 2026-05-19 US disclosed
CN-120590466-B Compound of targeted fibroblast activation protein and application thereof 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 2026-05-12 CN disclosed
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof TERREMOTO BIOSCIENCES, INC. (US) 2026-03-10 US disclosed
EP-4698530-A1 NK3 MODULATORS AND USES THEREOF Kallyope, Inc. (US) 2026-02-25 EP disclosed
EP-0356234-A2 New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-02-28 EP disclosed
EP-0110484-B1 DERIVATIVES OF AMINOPYRIDINECARBOXYLIC ACIDS, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Simes S.p.A. (IT) 1987-09-02 EP disclosed
EP-0076530-B1 NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1985-12-11 EP disclosed
US-4528296-A Derivatives of aminopyridinecarboxylic acids and pharmaceutical compositions containing them SIMES, SOCIETA ITALIANA MEDICINALLE SINTETICI (IT) 1985-07-09 US disclosed
EP-0110484-A1 Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them Simes S.p.A. (IT) 1984-06-13 EP disclosed
EP-0076530-A2 Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1983-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630497-B2 Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient MDH2, MDH1, ME2 GABRP 3578/4885GABRD 3689/4885GABRA1 4061/4885
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 LCLAT1, LPCAT1, ACAT2 GABRP 4471/4885GABRD 4317/4885GABRA1 3861/4885
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof AKT1, AKT2, AKT3 GABRP 1444/4885GABRD 3184/4885GABRA1 2249/4885
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof DGAT2, DGAT1, SOAT2 GABRP 2658/4885GABRD 1170/4885GABRA1 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.